greeksoup/ stock research
Stock research / United States / BNTX / Year to 31 December 2024

BioNTech SE (BNTX) annual results, year to 31 December 2024: revenue EUR 2,751 million, from the 20-F

BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2024 it reported revenue of EUR 2,751 million ($3.0 billion at the year's average rate), down 28.0% on the year before. Its profit attributable to shareholders was EUR -665 million, and diluted earnings per share EUR -2.77.

Revenue
EUR 2,751 million
-28.0% on the year
FY2017FY2024
Operating margin
-47.8%
18.1% a year earlier
FY2017FY2024
Net income
EUR -665 million
FY2017FY2024
Diluted EPS
EUR -2.77
FY2017FY2024

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2023Dec 2024
Revenue3,8192,751
Cost of sales600541
Research and development1,7832,254
Operating profit690-1,314
Finance costs23.927.4
Profit before tax1,186-678
Income tax256-12.4
Profit for the year930-665
Profit attributable to shareholders930-665
Filing20-F20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2023Dec 2024
Diluted EPS3.83-2.77
Basic EPS3.87-2.77
Filing20-F20-F

EUR per ordinary share, as filed.

Cash flow

Year toDec 2023Dec 2024
Cash from operations5,371208
Purchase of property, plant and equipment249286
Free cash flow5,122-78.8
Cash from investing-6,954-2,081
Cash from financing-779-45.9
Depreciation and amortisation183298
Dividends paid0.00.0
Filing20-F20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2023Dec 2024
Funded by
Equity attributable to shareholders20,24619,411
Borrowings, as filed219254
Lease liabilities217254
Other liabilities2,3252,610
Total equity and liabilities23,00622,530
Owned
Property, plant and equipment757935
Goodwill362381
Cash and cash equivalents11,6649,762
Trade and other receivables2,1561,464
Inventories358283
Other assets7,7109,705
Total assets23,00622,530
Filing20-F20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2023Dec 2024
Operating margin18.1%-47.8%
Net margin24.4%-24.2%
Free cash flow margin134.1%-2.9%
Return on year-end equity4.6%-3.4%
Effective tax rate21.6%n/a
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2024, filed 30 July 2026: the filing. The figures are in euros as filed.